MedTrace Logo

Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients

NCT00714376 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2012-10-31

No results posted yet for this study

Summary

The purpose of this study is to assess the response to Taxotere (docetaxel) chemotherapy given as a primary treatment to patients with early and rapid PSA rising after prostatectomy for high risk disease.

Conditions

Interventions

DRUG

Docetaxel

75 mg/m2 iv every 3 weeks for 8 cycles

Sponsors & Collaborators

  • CHU de Quebec-Universite Laval

    lead OTHER

Principal Investigators

  • Yves Fradet, MD · Centre Hospitalier Universitaire de Quebec (CHUQ)

  • Pierre Ouellet, MD · CHU de Quebec-Universite Laval

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714376 on ClinicalTrials.gov